Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study

• Verfasst von: Thaler, Josef [VerfasserIn]
• Verfasst von: Hofheinz, Ralf-Dieter [VerfasserIn]
• Titel: Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
• Verf.angabe: Josef Thaler, Meinolf Karthaus, Laurent Mineur, Richard Greil, Henry Letocha, Ralf Hofheinz, Eva Fernebro, Erick Gamelin, Ana Baños and Claus-Henning Köhne
• E-Jahr: 2012
• Jahr: 29 September 2012
• Umfang: 10 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 15.10.2018
• Titel Quelle: Enthalten in: BMC cancer
• Ort Quelle: London : BioMed Central, 2001
• Jahr Quelle: 2012
• Band/Heft Quelle: 12(2012), Artikel-ID 438
• ISSN Quelle: 1471-2407
• DOI: doi:10.1186/1471-2407-12-438
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1581880634

Abstract

Integument-related toxicities are common during epidermal growth factor receptor (EGFR)-targeted therapy. Panitumumab is a fully human monoclonal antibody targeting the EGFR that significantly improves progression-free survival when added to chemotherapy in patients with metastatic colorectal cancer who have wild-type (WT) KRAS tumours. Primary efficacy and tolerability results from a phase II single-arm study of first-line panitumumab plus FOLFIRI in patients with metastatic colorectal cancer have been reported. Here we report additional descriptive tolerability and quality of life data from this trial.